Multicenter Observational Study of Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Rare Driver Gene Mutation

2019 ◽  
Author(s):  
Keyword(s):  
Lung Cancer ◽  
Observational Study ◽  
Small Cell Lung Cancer ◽  
Gene Mutation ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Driver Gene ◽  
Small Cell Lung ◽  
Multicenter Observational Study ◽  
Nsclc Patients

Multicenter observational study of erlotinib therapy (OBSTAR) for non small-cell lung cancer: A GFPC study

Lung Cancer ◽  
2011 ◽  
Vol 74 (2) ◽  
pp. 264-267 ◽  
Author(s):  
A. Vergnenègre ◽  
I. Monnet ◽  
C. Chouaïd ◽  
J. Hureaux ◽  
J. Mazières ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Observational Study ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Multicenter Observational Study ◽  
Erlotinib Therapy

scholarly journals Toripalimab in an advanced non-small cell lung cancer patient with poor general condition after multiline treatment: a case report

2021 ◽  
Vol 49 (10) ◽  
pp. 030006052110429
Author(s):  
Yuling He ◽  
Tongtong An
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
General Condition ◽  
Single Agent ◽  
Small Cell ◽  
Poor Performance Status ◽  
Driver Gene ◽  
Small Cell Lung ◽  
Nsclc Patients

Several clinical trials have proven that immunotherapy can improve survival and benefit non-small cell lung cancer (NSCLC) patients. In patients who progress after chemotherapy, immune checkpoint inhibitor (ICI) monotherapy can prolong overall survival compared with patients receiving single-agent chemotherapy. A 61-year-old man diagnosed with advanced NSCLC and without driver variants received first-line chemotherapy but experienced recurrence. During subsequent treatment, the disease progressed rapidly, and his general condition deteriorated; therefore, toripalimab monotherapy was initiated. Surprisingly, he responded well, and symptoms were relieved after several treatment cycles despite pseudoprogression, shown in chest images. For driver gene-negative NSCLC patients who progress after chemotherapy and who develop poor performance status (PS), ICIs are an option to alleviate symptoms and improve survival. Furthermore, immunotherapy in patients with pseudoprogression may also provide a survival benefit.

scholarly journals Stereotactic Ablative Radiotherapy for stage I histologically proven non-small cell lung cancer: An Italian multicenter observational study

Lung Cancer ◽  
2014 ◽  
Vol 84 (3) ◽  
pp. 248-253 ◽  
Author(s):  
Umberto Ricardi ◽  
Giovanni Frezza ◽  
Andrea Riccardo Filippi ◽  
Serena Badellino ◽  
Mario Levis ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Observational Study ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Stage I ◽  
Stereotactic Ablative Radiotherapy ◽  
Small Cell Lung ◽  
Multicenter Observational Study
Sign in / Sign up

Export Citation Format

Share Document